Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care


Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (FRANKFURT:FME)(NYSE:FMS), the worlds’ largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).

In July 2010, IBI announced the signing of a definitive license and supply agreement whereby Fresenius Medical Care was offered an exclusive worldwide license to apply IBI’s EndexoTM technology to various components – including dialyzers and blood lines – of their chronic dialysis circuits for treating patients with end stage renal disease. This agreement has now been extended to include the acute dialysis market.

Subscribe to get the latest news